Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + paricalcitol
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
pembrolizumab + paricalcitol is an investigational combination therapy being evaluated for the treatment of resectable pancreatic cancer. Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as a checkpoint inhibitor to enhance the body's immune response against tumor cells. Paricalcitol is a synthetic analog of calcitriol and a selective vitamin D receptor (VDR) agonist. In the context of pancreatic cancer, paricalcitol is used to potentially reprogram the tumor stroma, reducing fibrosis and improving the infiltration of immune cells and the delivery of co-administered agents. This combination is notably being studied by the M.D. Anderson Cancer Center in the neoadjuvant setting, often in conjunction with standard chemotherapy regimens like gemcitabine and nab-paclitaxel.
- Brand names
- KeytrudaZemplar
- Other names
- pembrolizumab and paricalcitol
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on pembrolizumab + paricalcitol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + paricalcitol.